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Abstract
Purpose A joint effort of the European Association of Nuclear Medicine (EANM) and the European Academy of Neurology
(EAN) aims at clinical guidance for the use of FDG-PET in neurodegenerative diseases. This paper addresses the diagnostic
utility of FDG-PET over clinical/neuropsychological assessment in the differentiation of the three forms of primary progressive
aphasia (PPA).
Methods Seven panelists were appointed by the EANM and EAN and a literature search was performed by using harmonized
PICO (Population, Intervention, Comparison, Outcome) question keywords. The studies were screened for eligibility, and data
extracted to assess their methodological quality. Critical outcomes were accuracy indices in differentiating different PPA clinical
forms. Subsequently Delphi rounds were held with the extracted data and quality assessment to reach a consensus based on both
literature and expert opinion.
Results Critical outcomes for this PICO were available in four of the examined papers. The level of formal evidence supporting
clinical utility of FDG-PET in differentiating among PPAvariants was considered as poor. However, the consensual recommen-
dation was defined on Delphi round I, with six out of seven panelists supporting clinical use.
Conclusions Quantitative evidence demonstrating utility or lack thereof is still missing. Panelists decided consistently to provide
interim support for clinical use based on the fact that a typical atrophy or metabolic pattern is needed for PPA according to the
diagnostic criteria, and the synaptic failure detected by FDG-PET is an earlier phenomenon than atrophy. Also, a normal FDG-
PET points to a non-neurodegenerative cause.
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Introduction
In the lack of clinical guidelines for the use of FDG-PET to
diagnose dementing neurodegenerative conditions, the
European Association of Nuclear Medicine (EANM) and the
European Academy of Neurology (EAN) launched a joint
effort aimed at providing clinicians with clinical guidance
for using the exam. To this avail, a set of 21 clinical questions
was defined to perform literature searches and assessment of
the evidence supporting FDG-PET clinical use, and feeding a
group of experts defining consensual [1].
In this paper, we report the availability of evidence
supporting the use of FDG-PET for the differential diagnosis
between different forms of primary progressive aphasia
(PPA). PPA is divided into clinical variants based on specific
speech and language features characteristic of each subtype.
Clinical criteria for the three variants of PPA—nonfluent/
agrammatic, semantic, and logopenic—were developed by
an international group of PPA investigators [2]. This classifi-
cation can be further specified as Bimaging-supported^ if the
expected pattern of atrophy or hypometabolism is found, and
Bwith definite pathology^ if pathologic or genetic data are
available. Although FDG-PET is part of the classification de-
scribed by Gorno-Tempini and colleagues’, criteria [2] were
not based on quantitative literature analysis. Nevertheless,
FDG-PET is used on a regular basis in clinical practice for
the diagnosis of PPA types.
In this study, we thus assessed the quality of available ev-
idence supporting the utility of FDG-PET in the differential
diagnosis of PPA variants, which is relevant for indicating a
diagnosis and prognosis in individual patients.
Methods
EANM and EAN appointed respectively four and three
panelists to produce recommendations based on the incre-
mental value of FDG-PET, as added on clinical-
neuropsychological examination, to differentiate among
clinical presentations (non-fluent/agrammatic form, seman-
tic dementia, logopenic aphasia). Consensus recommenda-
tions were developed through a Delphi procedure [1],
where panelists voted based on the information about the
availability and quality of evidence, assessed by an inde-
pendent methodological group [3], and on their own
expertise.
Briefly, we performed literature searches using harmonized
PICO (Population, Intervention, Comparison, Outcome) ques-
tion keywords edited by panelists; we screened the studies for
eligibility, extracted the data to assessed their methodological
quality, and provided an evidence assessment consistent with
the EFNS guidance [4] in the specific context of FDG-PET
studies (this issue) [3].
PICO question
For this paper, the PICO question was whether FDG-PET
should be performed, as adding diagnostic value (in terms of
accuracy, and versus pathology or biomarkers of brain amy-
loidosis), as compared to standard clinical/neuropsychological
assessment alone, to differentiate among clinical presentations
(non-fluent/agrammatic form, semantic dementia, logopenic
aphasia) and to obtain indirect information on the molecular
pathologies in patients with primary aphasias. Note that, with-
in the whole initiative, the incremental diagnostic value of
FDG-PET versus clinical diagnosis was meant in terms of in-
creased accuracy of the nosological diagnosis. Other exams,
and particularly amyloid PET or CSF biomarkers in this case,
were expressively not included in the PICO question, nor in the
Delphi sessions, not being the focus of the project.
Eligibility criteria
Only original full papers published in English on international
impacted journals were considered, excluding reviews, man-
agement guidelines, abstracts, and gray literature. Any sample
size was allowed if pathology was the gold standard for diag-
nosis. Otherwise, the minimum sample sizes for including
papers was five.
Literature search
Electronic search strategy, developed and tested with panel-
ists, was performed through predefined strings, specific to the
PICO question, and including a selection of terms taken from
a largely inclusive literature selection, in order to pick all
variants for the same keyword [3].
Literature searches were performed using the Medline and
Embase databases, and included literature published by April
2016. In reporting the findings of this review, we adhered to
the standards of the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) [5]. A first indepen-
dent screening of all included studies was performed by a
neurologist, who could include additional papers based on
personal knowledge or tracking from references of papers.
The full texts of potentially eligible studies were then inde-
pendently reassessed for eligibility by the methodological
team.
Eur J Nucl Med Mol Imaging
Data extraction and quality assessment
We extracted data to evaluate the quality of evidence in sup-
port to the clinical use of FDG-PET for PPA as described by
Boccardi and colleagues [3]. Data extractors for this review
were SO and FG. The quality of evidence was assessed con-
sensually within the methodological group based on study
design, gold/reference standard, FDG-PET image assessment
(visual or semi-quantitative methods), risk of bias, index test
imprecision, applicability, effect size, and effect inconsistency.
Critical outcomes were validated measures of test perfor-
mance (accuracy, sensitivity, specificity, AUC, positive and
negative predictive values, and likelihood ratios). A final as-
sessment of relative availability of evidence was formulated,
keeping into account the evidence availability among all of the
21 PICOs. This ranking was summarized as very
poor/lacking, poor, fair, or good.
Results
Among the 156 papers identified and screened by the referent
panelist (FB), 16 reported the comparison of interest (Fig. 1)
and were included in the assessment. Critical outcomes for
this PICO were available in four of the examined papers
[6–9] (see Tables 1 and 2 PICO 16; data extraction table avail-
able at (https://drive.google.com/drive/u/0/folders/0B0_
JB3wzTvbpVFYtUGxHdGZWYmc).
Using SPM for the assessment of FDG-PET, Matias-Guiu
and colleagues [7] found that sensitivity, specificity, and ac-
curacy in differentiating all PPA variants were 86.2, 66.7, and
84%, respectively, using clinical diagnosis as reference diag-
nosis. In addition, they reported sensitivity, specificity, and
accuracy of SPM in differentiating among the three variants
of PPA. In detail, sensitivity was of 91.6% for av-PPA, 100%
for sv-PPA, and 78.6% for lv-PPA, specificity was 100% for
av-PPA, 93.1% for sv-PPA and 94.4% for lv-PPA and accu-
racy was 97% for av-PPA, 94% for sv-PPA, and 87% for lv-
PPA, respectively. They also reported a positive predictive
value of 96.1% (100% for av-PPA, of 60% for sv-PPA, and
91.7% for lv-PPA, respectively) and a negative predictive val-
ue of 33.3% (95.2% for av-PPA, 100% for sv-PPA, and 85%
for lv-PPA) (Table 1).
In their study, Nestor and colleagues [6] analyzed sensitiv-
ity and specificity of FDG-PET in predicting AD pathology in
five patients with autopsy confirmation. They found that bi-
lateral hypometabolism in the temporo-parietal cortex had
50% sensitivity in detecting AD pathology, while normal
temporo-parietal cortex had 38% sensitivity in detecting
non-AD pathology; bilateral hypometabolism in the
temporo-parietal cortex had 100% specificity in detecting
AD pathology and normal temporo-parietal cortex had
100% specificity in detecting non-AD pathology. Notably,
they also found that a unilateral left temporoparietal lesion
did not discriminate AD from FTLD, which is the reason for
the low sensitivities in spite of high specificity [6].
According to Whitwell and colleagues [8], using SPM and
ROI analyses, right lateral temporal hypometabolism, and
asymmetric hippocampal metabolism had 67 and 83% sensi-
tivity, respectively, and 100% specificity in predicting
amyloid-negative lv-PPA. Finally, in Taswell and colleagues
[9], using 3D SSP analyses, the PPV value in predicting AD
pathology was > 90% both in the lv-PPA and av-PPA, while
NPV was greater in av-PPA (96%) and sv-PPA (92%) than in
lv-PPA (81%). Both of these papers used amyloid PET for
confirming the underlying pathology.
The assessed studies caused concerns regarding risk of bias
for patient selection and the applicability of the index test, being
semi-quantitative methods for image analysis still uncommon in
clinical centers. The large heterogeneity of comparisons, besides
the very few studies and patient number, does not allow to
support consistency of results (Table 1 and 2).
Taking into account the availability of formal evidence for
all of the PICOs within the entire project, the level of evidence
supporting clinical utility of FDG-PET in differentiating
among PPA variants was considered as poor. The consensual
recommendation was defined on Delphi round I, with six out
of seven panelists supporting clinical use. Panelists kept that
specific patterns of atrophy and/or hypometabolism are nec-
essary for the diagnosis of PPA according to the diagnostic
criteria and FDG-PET is more sensitive than MRI [2].
Discussion
In this paper, we assessed the evidence on the clinical utility of
FDG-PET for the differential diagnosis between different
forms of PPA as an add on to clinical diagnosis, and without
comparison with additional exams. We show that literature
evidence for the use of FDG-PET in PPA is poor.
Nevertheless, six out of seven panelists, clinically experienced
in diagnosing PPA, supported clinical use of FDG-PET in the
first Delphi round, for differentiation between PPA types.
During the Delphi round, panelists indicated that clinically
it may be challenging to differentiate the three types of PPA.
Actually, since the publication of the diagnostic criteria by
Gorno-Tempini [2], many researchers showed overlap be-
tween the different PPA variants both clinically and on imag-
ing [11–13]. Still the PPA diagnostic criteria of Gorno-
Tempini clearly indicate that the typical atrophy or metabolic
pattern of the three main forms are mandatory for the diagno-
sis. In this context, the synaptic failure detected by FDG-PET
is an earlier phenomenon than atrophy and thus this tool was
still indicated by the panelists as extremely useful (Table 3). In
addition, the panelists remarked that a normal FDG-PET scan
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may also have diagnostic value, as it points to a non-
neurodegenerative cause of clinical aphasic symptomatology.
In their diagnostic criteria, Gorno-Tempini et al. make use of
MRI, FDG-PET, and SPECT as imaging modalities. Since
MRI is mandatory in all patients also for the exclusion of other
non-neurodegenerative underlying etiologies, some of the pa-
tients might show (onMRI) a pattern of atrophy already clearly
suggestive for a subtype of PPA. A systematic investigation of
the potential added value of FDG-PET in patients with pattern
of atrophy already supporting the diagnosis of PPA is outside
the aim of the present study and should be addressed when
discussing a complete diagnostic algorithm for PPA. With re-
spect to perfusion SPECT, due to the worse resolution, SPECT
should not be performed when FDG-PET is available [14].
Considering the recent advances in molecular imaging and
currently available neuropathological biomarkers for
Alzheimer’s disease (AD), i.e., CSF abeta, tau, ptau, and amy-
loid PET, the focus of this paper covers only a part of the com-
parative analyses that should be performed to outline a complete
and cost-effective diagnostic algorithm. Indeed, the added value
of FDG-PET over both clinical/neuropsychological evaluation
and specific AD biomarkers needs to be addressed. Especially
since a negative amyloid marker firmly rules out AD, although
co-pathology of ADmay occur in sv-PPA and av-PPA, yielding
positive amyloid biomarkers, while the causative underlying
pathology may be non-AD (e.g., TDP43 or tau pathology).
The hypometabolic pattern on FDG-PET is supportive in these
cases providing information on the extent and localization of
neuronal dysfunction, and thus the endophenotype of neuronal
injury. In this way, FDG-PETmay give indirect information on a
supposedly underlying molecular pathology, such as TDP43
pathology in semantic dementia. Actual and direct information
on the underlying neuropathology naturally requires more spe-
cific biomarker and/or genetic analysis. All in all, though, the
aim of the EANM-EAN initiative, and of this paper, was limited
to assessing the incremental value of FDG-PET over clinical
assessment, to give a guideline specific to the use of FDG-
PET in a clinical setting. We should also consider that both
CSF analysis as well as amyloid PET are not widely available
in all memory clinics yet, whereas FDG-PET is a widely used
technique also in other specialties such as oncology, and there-
fore widely available in most memory clinics. In the future,
when CSF analysis, amyloid PET, and possibly other neurode-
generative biomarkers and/or tracers (i.e., amyloid and/or tau)
become widely available for clinical purposes, a formal compar-
ison with FDG-PET will be needed to define a cost-effective
algorithm for diagnosis in PPA and dementia in general [15, 16].
Panelists alsomentioned that solving standardization issues
(e.g., for scan reading or normality threshold) may overcome
some of the current heterogeneity in FDG-PET diagnostic
performance [16, 17], as did also the other literature reviews
within the EANM-EAN Initiative [18–23].
The main limitation of the present study consisted in the
fact that the evidence assessment had to be performed, to the
best of our methodological resources, on literature character-
ized by important methodological limitations. In order to eval-
uate and compare quantitatively the incremental value of di-
agnostic tests, only papers reporting validated measures of test
performance could be included for analysis. Thereby, as many
as 12 out of the 16 papers found in the literature had to be
excluded, although they performed investigations potentially
relevant to the PICO question. Information on sensitivity and
specificity, and, even more, measures of test performance that
be independent on the prevalence of the disease in the
Fig. 1 PRISMA flowchart of
selected papers for PICO 16
regarding requirement of semi-
automated assessment (adapted
from Moher et al. 2009) [5]
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population (i.e., PPV, NPV, or negative and positive likelihood
ratios) are mandatory to allow assessment of incremental di-
agnostic value, and thus the definition of evidence-based di-
agnostic guidelines. To allow comparison of diagnostic
methods such as FDG-PET, we encourage research groups
to compute and report these critical outcome measures in fu-
ture publications, since this can usually be easily donewith the
data normally collected in this kind of study.
On the other hand, the lack of direct quantification of patient
outcomes (health, quality of life, mortality, institutionalization)
following FDG-PET-based diagnosis is a main limitation not
solvable in the short term. However, even accepting accuracy
studies as proxies for more appropriate patient management
[24, 25], many limitations remain. Indeed, demonstration of
diagnostic improvement after FDG-PET is limited by the lack
of pathology confirmation and of head-to-head comparison be-
tween FDG-PET and clinical assessment versus the same gold
standard [3]. In addition, the frequent use of mere baseline
clinical diagnosis as the reference standard conveys the limita-
tion of the intrinsic circularity between hypometabolic patterns
and clinical syndromes, and prevents computation of test per-
formance independent of the actual prevalence of the disorder
in the examined population. This may be due to the absence of
stakeholders, specific to FDG-PET and the so-called ‘orphan’
drugs: no company ever having exclusivity on the radiophar-
maceutical, rigorous expensive studies are scarce.
Also for this set of reasons, these recommendations are de-
fined late compared to other diagnostic appropriate use criteria,
e.g., those for amyloid-PET [26], which are also based on ex-
pert consensus, being defined in the complete lack of data on
clinical utility.With frequent gaps in formal evidence, the use of
clinicians’ experience should at present be seen as interim
evidence.
Conclusions
Notwithstanding the heterogeneity of results and poor evidence
in the literature, consensus was achieved on Delphi Round I,
when six out of seven panelists (being experienced clinicians in
neurodegeneration of both neurology (EAN) and nuclear med-
icine (EANM)) supported clinical use of FDG PET in PPA.
With synaptic failure being an earlier phenomenon than atro-
phy, FDG-PET is particularly valuable for the differential diag-
nosis between different forms of primary progressive aphasia.
This recommendation may be weighted based on the availabil-
ity of other kinds of examination more directly investigating
underlying pathophysiology, which comparison was not the
focus of the present paper.
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Table 3 Availability of evidence
and panelists’ decisions
supporting the use of FDG-PET
in the differential diagnosis of
PPA variants
PICO Relative
availability
of evidence
Panelists’
recommendations
Main reasons
for final decision
16 – diagnosis of PPA Poor Yes More sensitive than MRI. Required
in PPA diagnostic criteria
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